OBJECTIVE: To define the relationship between autoantigen citrullination and different peptidylarginine deiminase (PAD) enzymes in rheumatoid arthritis (RA). METHODS: Citrullinated autoantigens were identified by immunoblotting control and ionomycin-activated human primary neutrophil lysate with RA sera. Autoantigen identity and citrullination sites were defined by mass spectrometry. PAD isoenzyme expression in human neutrophils was determined by immunoblotting. PAD substrate specificity was addressed in HL-60 cell lysates co-incubated with human recombinant PAD2, PAD3 and PAD4. RESULTS: Although prominent protein citrullination is observed in ionomycin-activated neutrophils, RA sera only recognised a limited number of these citrullinated molecules. Among these, the authors identified that β and γ-actins are citrullinated on at least 10 arginine residues, generating a novel 47 kDa species that is frequently recognised by RA autoantibodies. Interestingly, the authors showed that the PAD enzymes expressed in human neutrophils (ie, PAD2, PAD3 and PAD4) have unique substrate specificities, independent of their subcellular distribution. Thus, only PAD2 was able to citrullinate native β/γ-actin, while histone H3 was only citrullinated by PAD4. CONCLUSION: These studies identified β and γ-actins as novel citrullinated autoantigens in RA, allowing enzyme specificity against intracellular substrates to be addressed. The studies provide evidence that PAD enzymes have the intrinsic capacity to select unique protein targets. The authors propose that unique PAD specificity may play a role in autoantigen selection in RA.
OBJECTIVE: To define the relationship between autoantigen citrullination and different peptidylarginine deiminase (PAD) enzymes in rheumatoid arthritis (RA). METHODS: Citrullinated autoantigens were identified by immunoblotting control and ionomycin-activated human primary neutrophil lysate with RA sera. Autoantigen identity and citrullination sites were defined by mass spectrometry. PAD isoenzyme expression in human neutrophils was determined by immunoblotting. PAD substrate specificity was addressed in HL-60 cell lysates co-incubated with human recombinant PAD2, PAD3 and PAD4. RESULTS: Although prominent protein citrullination is observed in ionomycin-activated neutrophils, RA sera only recognised a limited number of these citrullinated molecules. Among these, the authors identified that β and γ-actins are citrullinated on at least 10 arginine residues, generating a novel 47 kDa species that is frequently recognised by RA autoantibodies. Interestingly, the authors showed that the PAD enzymes expressed in human neutrophils (ie, PAD2, PAD3 and PAD4) have unique substrate specificities, independent of their subcellular distribution. Thus, only PAD2 was able to citrullinate native β/γ-actin, while histone H3 was only citrullinated by PAD4. CONCLUSION: These studies identified β and γ-actins as novel citrullinated autoantigens in RA, allowing enzyme specificity against intracellular substrates to be addressed. The studies provide evidence that PAD enzymes have the intrinsic capacity to select unique protein targets. The authors propose that unique PAD specificity may play a role in autoantigen selection in RA.
Authors: Andrew Kinloch; Karin Lundberg; Robin Wait; Natalia Wegner; Ngee Han Lim; Albert J W Zendman; Tore Saxne; Vivianne Malmström; Patrick J Venables Journal: Arthritis Rheum Date: 2008-08
Authors: Michelle L Harris; Erika Darrah; Gordon K Lam; Susan J Bartlett; Jon T Giles; Audrey V Grant; Peisong Gao; William W Scott; Hani El-Gabalawy; Livia Casciola-Rosen; Kathleen C Barnes; Joan M Bathon; Antony Rosen Journal: Arthritis Rheum Date: 2008-07
Authors: E R Vossenaar; T R D Radstake; A van der Heijden; M A M van Mansum; C Dieteren; D-J de Rooij; P Barrera; A J W Zendman; W J van Venrooij Journal: Ann Rheum Dis Date: 2004-04 Impact factor: 19.103
Authors: Violeta Romero; Justyna Fert-Bober; Peter A Nigrovic; Erika Darrah; Uzma J Haque; David M Lee; Jennifer van Eyk; Antony Rosen; Felipe Andrade Journal: Sci Transl Med Date: 2013-10-30 Impact factor: 17.956
Authors: Erin E Witalison; Xiangli Cui; Anne B Hofseth; Venkataraman Subramanian; Corey P Causey; Paul R Thompson; Lorne J Hofseth Journal: J Pharmacol Exp Ther Date: 2015-01-29 Impact factor: 4.030
Authors: Mandar Bawadekar; Daeun Shim; Chad J Johnson; Thomas F Warner; Ryan Rebernick; Dres Damgaard; Claus H Nielsen; Ger J M Pruijn; Jeniel E Nett; Miriam A Shelef Journal: J Autoimmun Date: 2017-02-07 Impact factor: 7.094